Second to None in Business Excellence: Mary Kay Named #2 on the Forbes 2026 Best Customer Service List
10.2.2026 17:01:00 CET | Business Wire | Press Release
Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, entered 2026 with momentum, securing a top-tier distinction on Forbes’ 2026 Best Customer Service list, where the company ranked #2 overall. The honor follows a standout year for Mary Kay, which concluded 2025 with a total of 25 global awards, underscoring its continued focus on corporate excellence, direct selling industry, social impact, environmental sustainability, science, and innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210599426/en/
Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, entered 2026 with momentum, securing a top-tier distinction on Forbes’ 2026 Best Customer Service list, where the company ranked #2 overall. (Image Courtesy: Mary Kay Inc.)
The recent recognition highlights Mary Kay’s enduring commitment to putting the customer at the heart of everything it does, from seamless digital support to personalized beauty advice. The Forbes Best Customer Service ranking spotlights organizations that have set the gold standard for responsiveness, empathy, and excellence in service delivery – and Mary Kay’s placement at number two reflects a remarkable year of business transformation.
“Every interaction with our customers is an opportunity to make someone feel seen, supported, and valued,” said Ryan Rogers, CEO of Mary Kay Inc. “Climbing to the No. 2 spot in the Forbes ranking is a strong validation of our people-powered culture and demonstrates the significance of what we can accomplish together. It speaks to the second-to-none reputation of our Independent Beauty Consultants, the passion of our customer service teams, and company values built on service and making time for others. That foundation is what inspires us to consistently deliver unforgettable customer experiences through our tried-and-true products.”
“Our Best Customer Service list relies on 3.8 million customer ratings each year to capture how real users rate thousands of brands and products,” said Forbes Assistant Managing Editor Alan Schwarz, who oversees the annual list. “More than 3,500 different brands were reviewed. To even make the top 300 list is an achievement — Mary Kay placing No. 2 overall indicates just how highly its customers feel about the company."
The Forbes recognition is the latest of a series of reputation awards garnered by Mary Kay in 2025:
Corporate Excellence
- Forbes #2 | Best Customer Service list
- Newsweek | America’s Greatest Workplaces for Women 2025
- Newsweek | America’s Greatest Workplaces 2025
- WWD Beauty Inc. #11 | The 2024 Top 100 Beauty Companies
- Happi #13 | Top 50 U.S. Companies
- Forbes Diamonds 2025 – Mary Kay Poland
- EXPANSIÓN | 2025 Compliance Awards – Mary Kay Spain
- China Association for Business Culture | 2025 Enterprise of Excellence Award – Mary Kay China
Brand Performance
- Euromonitor International #1 | Direct Selling Brand of Skin Care and Color Cosmetics in the World1 for three consecutive years (2023, 2024, 2025)
- Euromonitor International #1 Brand of Facial Make-Up in Latin America2
- Euromonitor International #1 Brand of Lip Products in Latin America3
- Euromonitor International #1 Brand of Skincare and Color Cosmetics in Mexico4
- Euromonitor International #1 Brand of Color Cosmetics in Mexico5
- Nielsen | #1 Brand in Foundations in Brazil
- Nielsen | #1 Brand in Makeup in Brazil
- 2025 Superbrands | Mary Kay Slovakia and Mary Kay Czech Republic
Direct Selling & Innovation
- Respected Direct Selling Enterprise 2025 Award – Mary Kay China
- Direct Selling News (DSN) | 2025 DSN 40 Under 40: Megan Gregg for Legal Excellence
- Direct Selling News (DSN) | 2025 DSN 40 Under 40: Julia Santosuosso for Corporate Social Responsibility Impact
- German Direct Selling Association (BDD) | “2025 Innovation” Award for Mary Kay’s AI-powered Foundation Finder – Mary Kay Germany
Social Impact & Environmental Sustainability
- Forbes #9 | Best Brands for Social Impact list – 2025
- Golden Bee | 2025 Outstanding Corporate Sustainability Report for "Gender Equality Information Disclosure” Award – Mary Kay China
- Cemefi | Distintivo ESR® Socially Responsible Company (Empresa Socialmente Responsable) – Mary Kay Mexico (2024, 2025)
- The Dallas Entrepreneurship Center (DEC) Network State of Entrepreneurship | “Large Corporation of the Year” Award
- Baylor Scott & White Dallas Foundation | “Circle of Care” Award.
***
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X.
About Forbes
Forbes is an iconic global media brand that has symbolized success for over a century. Fueled by journalism that informs and inspires, Forbes spotlights the doers and doings shaping industries, achieving success and making an impact on the world. Forbes connects and convenes the most influential communities ranging from billionaires, business leaders and rising entrepreneurs to creators and innovators. The Forbes brand reaches more than 140 million people monthly worldwide through its trusted journalism, signature ForbesLive events and 49 licensed local editions in 81 countries.
###
1 “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”
2 “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”
3 “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”
4 “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”
5 “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”
View source version on businesswire.com: https://www.businesswire.com/news/home/20260210599426/en/
Contacts
Mary Kay Inc. Corporate Communications
newsroom.marykay.com
972.687.5332 or media@mkcorp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom